As of 2026-05-20, the EV/EBITDA ratio of Acceleron Pharma Inc (XLRN) is -41.25. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. Acceleron's latest enterprise value is 10,456.47 mil USD. Acceleron's TTM EBITDA according to its financial statements is -253.46 mil USD. Dividing these 2 quantities gives us the above Acceleron EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.1x - 14.4x | 12.4x |
| Forward P/E multiples | 14.5x - 23.1x | 16.5x |
| Fair Price | (55.30) - (55.04) | (54.98) |
| Upside | -130.9% - -130.8% | -130.8% |
| Date | EV/EBITDA |